According to a new report published by K D Market Insights, titled, “Human recombinant insulin Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global human recombinant insulin market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The increasing prevalence of diabetes and the rising demand for effective insulin therapies. Additionally, advancements in biotechnology and genetic engineering have led to the development of human recombinant insulin, offering safer and more reliable treatment options which are the major factors augmenting the growth of the global human recombinant insulin market.

The increasing prevalence of diabetes worldwide is a major driver. The growing diabetic population, fueled by sedentary lifestyles, unhealthy dietary habits, and genetic factors, creates a significant demand for insulin therapies are further expected to create ample growth opportunities for the global human recombinant insulin market during the forecast period i.e., 2023-2032. Moreover, the mounting research and development efforts for drug discovery and development in the field of diabetes has propelled market expansion., favorable reimbursement policies and government initiatives, is expected to contribute towards the market growth during the period.

The North America region accounted for the largest share in the global human recombinant insulin market in 2022. The region is further projected to continue dominating in the market and also register the highest CAGR in the market during the forecast period. This can be attributed to the high prevalence of diabetes, favorable reimbursement policies, and advanced healthcare infrastructure.

According to product type, long-acting human insulin segment accounted for the largest market share in the human recombinant insulin market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.

The global human recombinant insulin market is segmented into product type, brand, distribution channel and region. Based on product type, the market is bifurcated into rapid-acting human insulin, short-acting human insulin, intermediate-acting human insulin, long-acting human insulin, and premixed human insulin. Based on brand, it is classified into insuman, humulin, novolin, other brands. Based on distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online pharmacies.

The global human recombinant insulin market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).

Key Insights of Human recombinant insulin Market

• On the basis of product type, long-acting human insulin segment accounted for the largest market share in the human recombinant insulin market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
• On the basis of region, North America accounted for the largest share in the global human recombinant insulin market in 2022. The region is further projected to continue dominating in the market during the forecast period.
• On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.

Some of the major human recombinant insulin companies profiled in the report include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd., and Dongbao Enterprise Group Co., Ltd.

Related Reports :-

https://www.kdmarketinsights.com/reports/patient-handling-equipment-market/7095

https://www.kdmarketinsights.com/reports/bone-cement-and-glue-market/7058

https://www.kdmarketinsights.com/reports/atrial-fibrillation-market/7055

https://www.kdmarketinsights.com/reports/alexandrite-gemstone-lasers-market/7053